Track NextCure, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NextCure, Inc. NXTC · Stock Open NextCure, Inc. in new tab

6.40 USD
EPS
-6.78
P/B
0.64
ROE
-204.56
Beta
1.20
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-6.78
Book Value9.97
Price to Book0.64
Debt/Equity38.41
% Insiders18.797%
Estimates
Forward P/E-1.09
Forward EPS-5.90

DCF valuation

Model fair value for NextCure, Inc. (NXTC)
Result
Sign in to run the valuation for NXTC.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

NextCure, Inc. Logo NextCure, Inc. Analysis (NXTC)

United States Health Care Official Website Stock

Is NextCure, Inc. a good investment? NextCure, Inc. (NXTC) is currently trading at 6.40 USD.

Earnings Schedule: NextCure, Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -5.90.

Investor FAQ

Does NextCure, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NextCure, Inc.?

NextCure, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -6.78.

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Exchange Ticker
NMS (United States) NXTC
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 14, 2025 1:12
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion